EDTA chelation effects on urinary losses of cadmium, calcium, chromium, cobalt, copper, lead, magnesium, and zinc

Biological Trace Element Research

Volumn 83, Issue 3, 2001, Pages 207-221

  Waters, Robert S ^a   Bryden, Noella A ^a   Patterson, Kristine Y ^a   Veillon, Claude ^a   Anderson, Richard A ^a  

^a BELTSVILLE HUMAN NUTRITION RESEARCH CENTER   (United States)

Author keywords

Cadmium; Chelation therapy; Chromium; Cobalt; EDTA; Iron; Lead; Magnesium; Zinc

Indexed keywords

CADMIUM; CALCIUM; CHROMIUM; COBALT; COPPER; EDETIC ACID; LEAD; MAGNESIUM; ZINC;

ADULT; AMINO ACID METABOLISM; ARTICLE; BINDING AFFINITY; CHELATION; CLINICAL ARTICLE; DRUG EXCRETION; FEMALE; HUMAN; LEAD POISONING; LIGAND BINDING; MALE; METAL BINDING; PROTEIN CONTENT; PROTEIN PROTEIN INTERACTION; URINALYSIS; URINARY EXCRETION; ZINC DEFICIENCY;

AGED; CADMIUM; CALCIUM; CHELATING AGENTS; CHROMIUM; COBALT; COPPER; EDETIC ACID; HUMANS; LEAD; MAGNESIUM; METALS; MIDDLE AGED; ZINC;

EID: 0035663911     PISSN: 01634984     EISSN: None     Source Type: Journal    
DOI: 10.1385/BTER:83:3:207     Document Type: Article

References (66)

1. Urinary trace and toxic elements and minerals in untimed urine specimens relative to urine creatinine
2. Human zinc deficiency
3. Volumetric methods based on complex-formation reactions
4. The protocol for the safe and effective administration of EDTA and other chelating agents for vascular disease, degenerative disease and metal toxicity
5. Metabolism of carbon 14 labeled ethylenediaminetetraacetic acid in human beings
6. Effect of exercise (running) on serum glucose, insulin, glucagon and chromium excretion
7. Prediction of creatinine clearance from serum creatinine
8. Monitoring renal function during EDTA chelation therapy
9. Ischemic heart disease: Toward a unified theory
10. Mineral excretion associated with EDTA chelation therapy
11. Monitoring renal function during EDTA Chelation therapy
12. EDTA chelation therapy does not selectively increase chromium losses
13. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes
14. Chromium, glucose intolerance and diabetes
15. Reversal of corticosteroid-induced diabetes mellitus with supplemental chromium
16. Chromium and diabetes
17. Essential trace elements, chromium, copper, iron, zinc and selenium, and cardiovascular diseases
18. Enhancement of lead excretion in humans by disodium calcium ethylenediaminetetraacetic acid
19. Antihypertensive effects of metal binding agents
20. Cadmium hypertension, its reversal by a zinc chelate
21. Blood lead and coronary heart disease among elderly men in Zutphen the Netherlands
22. The effects of intravenous disodium EDTA on blood cholesterol in a private practice environment
23. The Improvement in renal function following EDTA chelation and multivitamin-trace mineral therapy: A study in creatinine clearance
24. EDTA chelation therapy: A retrospective study of 2, 870 patients
25. Analysis of zinc data from the second National Health and Nutrition Examination Survey (NHANES II)
26. Zinc intake of the U.S. population: Findings from the third National Health and Nutrition Examination Survey, 1988-1994
27. Whole body surface loss of trace metals in normal males
28. The long term use, side effects and toxicity of disodium EDTA
29. Acute versenate nephrosis
30. Treatment of angina pectoris with disodium EDTA
31. Chelation endarterectomy for occlusive atherosclerosis
32. The "clinical change" in patients treated with EDTA chelation plus multivitamin trace mineral supplementation
33. EDTA chelation therapy: Efficacy in heart disease
34. EDTA chelation therapy: Treatment of peripheral arterial occlusion, an alternative to amputation
35. Benefits of EDTA chelation therapy in atherosclerosis: A retrospective study of 470 patients
36. The correlation between EDTA chelation therapy and improvement in cardiovascular function: A meta-analysis
37. Carotid restenosis: A case for EDTA chelation
38. Renal artery stenosis reversal in a hypertensive individual, using a combination of EDTA chelation and multiple vitamin and trace mineral therapy
39. The "in vivo" dissolution of metastatic calcium: An approach to atherosclerosis
40. A practical method for the reduction of plasma cholesterol in man
41. Some mechanisms of EDTA on platelet aggregation
42. EDTA chelation therapy: An antioxidant strategy
43. Interactions of Mg and K on blood vessels: Aspects in view of hypertension
44. Intracellular free magnesium in erythrocytes of essential hypertension: Relation to blood pressure and serum divalent cations
45. Decreased cellular Mg2+ concentrations in a subgroup of hypertensives - Cell models for the pathogenesis of primary hypertension
46. Effect of intensive i.v. and oral magnesium supplementation on circulating ion levels, lipid parameters and metabolic control in Mg-depleted insulin-dependent diabetic patients (IDDM)
47. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
48. Insulin, cation metabolism and insulin resistance
49. Magnesium in diabetes mellitus
50. Prevalence of magnesium and zinc deficiencies in nursing home residents in Germany
51. Magnesium deficiency and increased fractional magnesium excretion in insulin-dependent diabetes mellitus-magnesium loading fraction and blood pressure
52. Intravenous magnesium sulphate in suspected acute myocardial infarction of the second Leicester Intravenous Magnesium Intervention Trial. (LIMIT-2)
53. Efficacy of intravenous magnesium in acute myocardial infarction in reducing arrhythmias and mortality. Meta-analysis of magnesium in acute myocardial infarction
54. Magnesium therapy in new-onset atrial fibrillation
55. The rationale of magnesium as alternative therapy for patients with acute myocardial infarction without thrombolytic therapy
56. Role of insulin resistance in human disease
57. The use of both "push and pull" mechanisms against free radical induced biological damage
58. The physiological role of zinc an antioxidant
59. Abnormal mitochondrial oxidative phosphorylation of ischemic myocardium reversed by Ca2+-chelating agents